DEP-HER2-lutetium(Starpharma)

N/A

Report date: 2025/11/07 11:34:02

Base Information

Drug NameDEP-HER2-lutetium(Starpharma)

Drug Alias NameHER2-targeted DEP antibody drug conjugate(Starpharma)177Lu-DEP HER2-lutetium

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionIonising radiation emittersReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesStarpharma Pty Ltd

China Registration ClassN/A

Develop Information

Active CompaniesStarpharma Pty Ltd

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A